

APPENDIX 1. SEROUS EPITHELIAL OVARIAN CANCER ONLY: DIFFERENCE-IN-DIFFERENCES ESTIMATES FOR STAGE AT DIAGNOSIS AND DELAYS IN TREATMENT AFTER THE AFFORDABLE CARE ACT						
	Difference-in-Differences					
	Overall post-ACA (95% CI)	Adjusted p-value	Early post-ACA (95% CI)	Adjusted p-value	Late post-ACA (95% CI)	Adjusted p-value
Women with Ovarian Cancer						
Uninsured	0.0 (-0.7-0.8)	0.87	1.5 (0.6-2.4)	0.001	-1.9 (-2.7, -1.0)	0.001
Early-stage at diagnosis	0.3 (-1.4-2.0)	0.74	1.0 (-1.0-2.9)	0.33	-0.8 (-2.8-1.3)	0.46
Treatment received within 30 days of diagnosis	2.4 (1.0-3.7)**	<0.001	2.2 (0.7-3.6)**	0.004	2.5 (0.9-4.1)**	0.002
Publicly-Insured Women with Ovarian Cancer						
Early-stage at diagnosis	0.0 (-3.1-2.9)	0.96	-0.4 (-3.8-3.1)	0.84	-1.5 (-6.2-3.2)	0.53
Treatment received within 30 days of diagnosis	2.5 (-0.3-5.2)	0.08	2.6 (-0.4-5.6)	0.09	2.3 (-0.8-5.5)	0.14
Privately-insured Women with Ovarian Cancer						
Early-stage at diagnosis	-1.3 (-5.2-2.7)	0.52	-1.2 (-5.6-3.3)	0.61	0.1 (-3.4-3.7)	0.95
Treatment received within 30 days of diagnosis	-1.2 (-1.5-3.8)	0.39	-1.8 (-4.6-1.1)	0.22	-0.3 (-2.9-3.5)	0.84
Non-white Women with Ovarian Cancer						
Uninsured	1.1 (-1.9-4.2)	0.45	-0.1 (-3.7-3.5)	0.96	2.8 (-0.6-6.2)	0.11
Early-stage at diagnosis	1.6 (-3.7-7.0)	0.56	0.7 (-5.4-6.7)	0.83	2.6 (-3.6-8.8)	0.41
Treatment received within 30 days of diagnosis	5.2 (0.4-9.9)	0.03	4.5 (-0.6-9.6)	0.08	5.8 (0.2-11.3)	0.04
White Women with Ovarian Cancer						
Uninsured	-0.1 (-0.9-0.6)	0.78	1.6 (0.7-2.5)	0.001	-1.7 (0.9-2.6)	<0.001
Early-stage at diagnosis	0 (-1.8-1.8)	0.98	1.0 (-1.0-3.1)	0.32	-1.3 (-3.5-0.8)	0.23
Treatment received within 30 days of diagnosis	2.2 (0.8-3.6)	0.002	2.0 (0.4-3.5)	0.01	2.4 (0.7-4.0)	0.006
ACA = Affordable Care Act Post-ACA = 2011-2015, early post-ACA = 2011-2013, late post-ACA 2014-2015 Within-arm difference compared to pre-ACA year: * Significant at p <0.05 level, ** Significant at p <0.01 level						

Smith AJB, Fader AN. Association of the Affordable Care Act with ovarian cancer care. Obstet Gynecol 2020;135.
The authors provided this information as a supplement to their article.

Difference-in-differences (DD) = (Intervention_{post-ACA} – Intervention_{pre-ACA}) – (Comparison_{post-ACA} – Comparison_{pre-ACA})

Statistical significance of within-arm pre-post difference and difference-in-differences adjusted for race/ethnicity, living in a rural area, area-level household income and education level, Charlson co-morbidity score, distance traveled for care, Census region, and care at an academic center.

APPENDIX 2. ALTERNATIVE TIME COMPARISON FOR DIFFERENCE-IN-DIFFERENCES ESTIMATES FOR STAGE AT DIAGNOSIS AND DELAYS IN TREATMENT AFTER THE AFFORDABLE CARE ACT						
	Intervention Group (Ages 21-64 years)		Comparison Group (Ages 65+ years)		Difference-in-Differences	
	2011-2013	2014-2015 % (95% CI)	2011-2013	2014-2015 % (95% CI)	Post	Adjusted p-value
Women with Ovarian Cancer						
Uninsured	7.9 (7.6-8.3)	4.4 (4.1-4.8)**	0.7 (0.6-0.8)	0.6 (0.5-0.8)	-3.4% (2.9-4.1)	<0.001
Early-stage at diagnosis	41.9 (41.2-42.6)	41.8 (41.0-42.7)	25.1 (24.4-25.7)	25.7 (24.9-26.5)	0% (-2.3-0.7)	0.28
Treatment received within 30 days of diagnosis	91.6 (91.2-92.0)	90.4 (89.9-90.8)**	85.3 (84.8-85.8)	83.2 (82.6-83.9)**	0.8 (-0.2-1.8)	0.10
Publicly-Insured Women with Ovarian Cancer						
Early-stage at diagnosis	35.1 (33.7-36.7)	37.2 (35.4-38.9)	24.9 (24.2-25.7)	25.6 (24.8-26.5)	1.4 (-1.0-3.8)	0.27
Treatment received within 30 days of diagnosis	86.9 (85.9-87.9)	86.2 (84.9-87.3)**	85.3 (84.7-85.9)	83.3 (82.6-84.0)*	1.2 (0.2-3.1)	0.20
Privately-insured Women with Ovarian Cancer						
Early-stage at diagnosis	44.0 (43.2-44.7)	43.3 (42.3-44.4)	26.6 (24.7-28.5)	27.3 (25.0-29.7)	-1.3% (-4.9-2.1)	0.44
Treatment received within 30 days of diagnosis	93.3 (92.9-93.7)	91.9 (91.3-92.4)	86.2 (84.7-87.5)	83.7 (81.7-85.5)**	1.2% (-0.1-3.2)	0.21
Non-white Women with Ovarian Cancer						
Uninsured	10.1 (9.1-11.3)	6.0 (5.1-7.1)**	2.1 (1.5-2.9)	1.6 (1.1-2.5)	-3.5 (-5.7, -1.4)	0.001
Early-stage at diagnosis	40.1 (38.3-41.9)	41.2 (39.1-43.2)	24.0 (22.0-26.1)	24.1 (21.7-26.6)	1.1 (-3.3-5.5)	0.61
Treatment received within 30 days of diagnosis	89.1 (87.9-90.1)	88.5 (87.1-89.7)	81.1 (79.2-82.9)	77.5 (75.1-79.7)**	3.0 (-0.2-6.2)	0.06
White Women with Ovarian Cancer						
Uninsured	7.5 (7.2-7.9)	4.1 (3.8-4.5)**	0.6 (0.5-0.7)	0.5 (0.4-0.6)	-3.4 (-4.0,-2.8)	<0.001
Early-stage at diagnosis	42.2 (41.5-42.9)	41.8 (40.9-42.7)	25.2 (24.5-25.9)	25.9 (25.1-26.7)	-1.3 (-2.9-0.3)	0.12

Treatment received within 30 days of diagnosis	92.1 (91.7-92.4)	90.7 (90.1-91.1)**	85.8 (85.2-86.3)	83.9 (83.2-84.6)**	0.5 (-0.6-1.6)	0.35
<p>ACA = Affordable Care Act Post-ACA = 2011-2015, early post-ACA = 2011-2013, late post-ACA 2014-2015 Within-arm difference compared to pre-ACA year: * Significant at p <0.05 level, ** Significant at p <0.01 level Difference-in-differences (DD) = (Intervention_{post-ACA} – Intervention_{pre-ACA}) – (Comparison_{post-ACA} – Comparison_{pre-ACA}) Statistical significance of within-arm pre-post difference and difference-in-differences adjusted for race/ethnicity, living in a rural area, area-level household income and education level, Charlson co-morbidity score, distance traveled for care, Census region, and care at an academic center.</p>						

APPENDIX 3. AGE CLUSTERING ANALYSIS FOR DIFFERENCE-IN-DIFFERENCES ESTIMATES FOR STAGE AT DIAGNOSIS AND DELAYS IN TREATMENT AFTER THE AFFORDABLE CARE ACT						
	Difference-in-Differences					
	Overall post-ACA (95% CI)	Adjusted p-value	Early post-ACA (95% CI)	Adjusted p-value	Late post-ACA (95% CI)	Adjusted p-value
Women with Ovarian Cancer						
Uninsured	0.1 (-0.3-0.5)	0.68	1.3 (0.8-1.8)	<0.001	2.2 (1.7-2.6)	<0.001
Early-stage at diagnosis	1.4 (0.2-2.6)	0.02	1.7 (0.4-3.1)	0.01	0.1 (-0.5-2.4)	0.20
Treatment received within 30 days of diagnosis	2.4 (1.7-3.1)	<0.001	2.0 (1.1-2.9)	<0.001	2.9 (1.9-3.8)	<0.001
Publicly-Insured Women with Ovarian Cancer						
Early-stage at diagnosis	2.7 (0.7-4.8)	0.01	2.1 (0.1-4.2)	0.04	3.4 (0.7-6.2)	0.02
Treatment received within 30 days of diagnosis	2.5 (1.5-3.5)	<0.001	2.0 (0.5-3.4)	0.009	3.2 (1.7-4.7)	<0.001
Privately-insured Women with Ovarian Cancer						
Early-stage at diagnosis	1.1 (-1.3-3.5)	0.35	1.6 (-1.0-4.3)	0.23	0.3 (-2.9-3.5)	0.84
Treatment received within 30 days of diagnosis	1.4 (0.2-2.7)	0.03	1.0 (-0.8-2.7)	0.27	2.1 (0.6-3.8)	0.009
Non-white Women with Ovarian Cancer						
Uninsured	1.5 (0.0-3.1)	0.06	0 (-1.4-1.5)	0.97	-3.6 (-5.0, -2.2)	<0.001
Early-stage at diagnosis	2.2 (-1.0-5.4)	0.19	1.7 (-2.0-5.5)	0.36	2.8 (-1.3-6.9)	0.17
Treatment received within 30 days of diagnosis	4.7 (2.4-6.9)	<0.001	3.5 (0.9-6.1)	0.01	6.4 (4.3-8.4)	<0.001
White Women with Ovarian Cancer						
Uninsured	0 (-0.4-0.4)	0.96	1.4 (0.8-1.9)	<0.001	-2.0 (-1.5, -2.5)	<0.001
Early-stage at diagnosis	1.3 (0.2-2.3)	0.02	1.8 (0.3-3.1)	0.02	0.5 (-0.9-2.0)	0.48
Treatment received within 30 days of diagnosis	2.1 (1.4-2.8)	<0.001	1.9 (1.0-2.8)	<0.001	2.4 (1.4-3.4)	<0.001
ACA = Affordable Care Act Post-ACA = 2011-2015, early post-ACA = 2011-2013, late post-ACA 2014-2015 Within-arm difference compared to pre-ACA year: * Significant at p <0.05 level, ** Significant at p <0.01 level						

Difference-in-differences (DD) = (Intervention_{post-ACA} – Intervention_{pre-ACA}) – (Comparison_{post-ACA} – Comparison_{pre-ACA})

Statistical significance of within-arm pre-post difference and difference-in-differences adjusted for race/ethnicity, living in a rural area, area-level household income and education level, Charlson co-morbidity score, distance traveled for care, Census region, and care at an academic center.

APPENDIX 4. REGRESSION RESULTS FOR THE CORE MODEL ANALYSIS OF THE IMPACT OF THE AFFORDABLE CARE ACT ON WOMEN WITH OVARIAN CANCERS		
	Regression Coefficient (95% CI)	p-value
Uninsured		
Women Ages 21-64 Years * Post-ACA (Treatment effect)	0.0 (-0.3-0.5)	0.70
Women Ages 21-64	-5.8 (-6.1, -5.5)	<0.001
Post-ACA	0.02 (-0.5-0.1)	0.19
Race/ethnicity	-0.8 (-1.0,-0.6)	<0.001
Non-urban area	-0.7 (-0.8-0.7)	0.86
Area-level household income	0.8 (0.7-0.9)	<0.001
Area-level educational attainment	0.9 (0.8-1.0)	<0.001
Distance traveled for care	0.3 (0.2-0.4)	<0.001
Charlston comorbidity score	0.3 (0.1-0.5)	0.002
Census Region	-0.7 (-0.8,-0.6)	<0.001
Treatment at an academic hospital	-1.1 (-1.3, -0.9)	<0.001
Early-Stage at Diagnosis		
Women Ages 21-64 Years * Post-ACA (Treatment effect)	1.4 (0.4-2.4)	0.007
Women Ages 21-64	15.1 (14.4-15.9)	<0.001
Post-ACA	2.3 (1.5-3.1)	<0.001
Insured	1.2 (-0.1-2.6)	0.07
Race/ethnicity	0.5 (0-1.1)	0.06
Non-urban area	-0.4 (-2.4-1.6)	0.71
Area-level household income	1.1 (0.8-1.4)	<0.001
Area-level educational attainment	-0.1 (-0.5-0.2)	0.49

Smith AJB, Fader AN. Association of the Affordable Care Act with ovarian cancer care. Obstet Gynecol 2020;135.

The authors provided this information as a supplement to their article.

©2020 American College of Obstetricians and Gynecologists.

Distance traveled for care	-0.4 (-0.6,-0.1)	0.004
Charlston comorbidity score	-0.2 (-0.7-0.3)	0.37
Census Region	-0.6 (-0.9, -0.3)	<0.001
Treatment at an academic hospital	-0.1 (-0.6-0.5)	0.85
Treatment within 30 Days of Diagnosis		
Women Ages 21-64 Years * Post-ACA (Treatment effect)	2.4 (1.7-3.0)	<0.001
Women Ages 21-64	4.4 (4.0-4.9)	<0.001
Post-ACA	-4.0 (-4.5, -3.5)	<0.001
Insured	-1.1 (-0.7,-1.5)	<0.001
Race/ethnicity	2.5 (1.7-3.4)	<0.001
Non-urban area	2.0 (0.8-3.3)	0.001
Area-level household income	0.1 (-0.1-0.3)	0.19
Area-level educational attainment	1.2 (1.0-1.5)	<0.001
Distance traveled for care	0.6 (0.4-0.7)	<0.001
Charlston comorbidity score	-1.3 (-1.6, -1.0)	<0.001
Census Region	0.3 (0.2-0.5)	<0.001
Treatment at an academic hospital	-0.2 (-0.6-0.1)	0.15

Smith AJB, Fader AN. Association of the Affordable Care Act with ovarian cancer care. Obstet Gynecol 2020;135.

The authors provided this information as a supplement to their article.

©2020 American College of Obstetricians and Gynecologists.

Page 8 of 9

APPENDIX 5. COUNTS OF OVARIAN CANCERS OVER TIME, 2004-2015						
	All Ovarian Cancer	Publicly-Insured	Privately-Insured	Uninsured	Non-white	White
Women, Ages 21-64 Years						
2004	6,064	874	4,790	400	589	5,426
2005	6,457	934	5,123	400	714	5,720
2006	6,565	972	5,180	413	700	5,821
2007	6,968	1,075	5,458	435	803	6,121
2008	7,006	1,097	5,460	449	794	6,175
2009	6,957	1,198	5,311	448	850	6,039
Total Pre-ACA	40,017	6,150	31,322	2,545	4,450	35,302
2011	7,239	1,352	5,320	567	890	6,274
2012	7,242	1,333	5,376	533	1,002	6,178
2013	7,435	1,422	5,373	640	1,123	6,240
2014	7,347	1,541	5,446	360	1,105	6,148
2015	7,337	1,558	5,487	292	1,107	6,135
Total Post-ACA	36,600	7,206	27,002	2,392	5,227	30,975
Women, Ages 65+ Years						
2004	4,891	4,286	580	25	376	4,486
2005	4,909	4,300	577	32	353	4,537
2006	5,109	4,491	593	25	394	4,701
2007	5,164	4,496	640	28	428	4,716
2008	5,611	4,916	667	28	471	5,105
2009	5,610	4,915	661	34	489	5,091
Total Pre-ACA	31,294	27,404	3,718	172	2,511	28,636
2011	5,597	4,846	718	33	570	4,998
2012	5,766	4,945	772	49	548	5,202
2013	6,202	5,383	776	43	625	5,551
2014	6,164	5,398	728	38	604	5,513
2015	6,087	5,338	708	41	625	5,419
Total Post-ACA	29,816	25,910	3,702	204	2,972	26,683

Smith AJB, Fader AN. Association of the Affordable Care Act with ovarian cancer care. Obstet Gynecol 2020;135.

The authors provided this information as a supplement to their article.

©2020 American College of Obstetricians and Gynecologists.

Page 9 of 9